PMID- 26316515
OWN - NLM
STAT- MEDLINE
DCOM- 20171010
LR  - 20181202
IS  - 1532-2750 (Electronic)
IS  - 1098-612X (Linking)
VI  - 18
IP  - 11
DP  - 2016 Nov
TI  - Clinical efficacy and safety following dose tapering of ciclosporin in cats with 
      hypersensitivity dermatitis.
PG  - 898-905
LID - 10.1177/1098612X15602523 [doi]
AB  - Objectives This study was designed to evaluate the efficacy and safety of 
      reducing ciclosporin (CsA) dosing frequency from daily to every other day (EOD) 
      or twice a week (TW) according to clinical response in cats with hypersensitivity 
      dermatitis (HD) and treated with CsA. Methods One hundred and ninety-one cats 
      with HD were given 7 mg/kg CsA daily for at least 4 weeks. Depending on clinical 
      response, the dosing frequency was tapered from daily to EOD over the next 4 
      weeks and further to TW for an additional 4 weeks. Safety was evaluated through 
      physical examinations, clinical pathology and the monitoring of adverse events 
      (AEs). Results The majority of cats were able to have their dose of CsA tapered 
      to either EOD (15.5%) or TW (62.9%) according to the clinical response. Observed 
      AEs were most frequently mild and self-limiting vomiting and diarrhea. A higher 
      percentage of AEs occurred with daily administration (73%) compared with other 
      dosing regimens (27%). Conclusions and relevance Following 4 weeks of daily 
      dosing at 7 mg/kg, CsA may be tapered to EOD or TW while maintaining the desired 
      therapeutic response in cats with HD. Additionally, CsA appears to be well 
      tolerated with fewer AEs at EOD or TW dosing. Establishing the lowest effective 
      dosing frequency of CsA improves the drug's safety profile.
FAU - Roberts, Elizabeth S
AU  - Roberts ES
AD  - 1 Novartis Animal Health US, Greensboro, NC, USA.
FAU - Tapp, Tiffany
AU  - Tapp T
AD  - 2 Veterinary Healing Arts, East Greenwich, RI, USA.
FAU - Trimmer, Ann
AU  - Trimmer A
AD  - 3 Animal Allergy and Dermatology Specialists, Las Vegas, NV, USA.
FAU - Roycroft, Linda
AU  - Roycroft L
AD  - 1 Novartis Animal Health US, Greensboro, NC, USA.
FAU - King, Stephen
AU  - King S
AD  - 1 Novartis Animal Health US, Greensboro, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160709
PL  - England
TA  - J Feline Med Surg
JT  - Journal of feline medicine and surgery
JID - 100897329
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Cat Diseases/*drug therapy/pathology
MH  - Cats
MH  - Cyclosporine/*administration & dosage
MH  - Dermatitis, Atopic/drug therapy/*veterinary
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule/veterinary
MH  - Female
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Male
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2015/09/01 06:00
MHDA- 2017/10/11 06:00
CRDT- 2015/08/29 06:00
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2015/08/29 06:00 [entrez]
AID - 1098612X15602523 [pii]
AID - 10.1177/1098612X15602523 [doi]
PST - ppublish
SO  - J Feline Med Surg. 2016 Nov;18(11):898-905. doi: 10.1177/1098612X15602523. Epub 
      2016 Jul 9.